amr industry alliance
The AMR Industry Alliance is one of the largest private sector coalitions set up to provide sustainable solutions to curb antimicrobial resistance, with over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations joining forces.
read moreWe drive and measure the life-sciences industry progress to curb antimicrobial resistance in four different areas:
shared goals
We are uniting efforts to reduce the development of antimicrobial resistance, invest in R&D to meet public health needs and improve access to antibiotics, vaccines and diagnostics.
progress report
We are working on our first progress report that will be published in January 2018. This report will serve to benchmark our progress, set targets for the future and identify gaps where further efforts may be required. Stay tuned!
in action
Our case studies provide snap-shots from across the life-sciences industry, share information on the tangible steps we are taking to invest in new research to develop new antibiotics and vaccines, prevent infection ,and improve appropriate use of antibiotics.
latest news
Multiple Alliance Members Co-sign the Canadian Declaration on Antimicrobial Resistance
The International Council of Biotechnology Associations (ICBA) supports the Canadian Declaration on Combatting Antimicrobial Resistance, signed by biopharmaceutical and diagnostic companies in Canada...
Read more
Report shows life sciences industry alliance is taking action to curb antimicrobial resistance, with more to come
The new AMR Industry Alliance of more than 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and trade associations launches its first progress report today. The re...
Read more
New Alliance to Drive and Measure Industry Progress to Curb Antimicrobial Resistance
New Industry Alliance brings together research-based pharmaceutical companies, generics, biotech and diagnostic companies, to drive and measure industry progress to curb antimicrobial resistance....
Read moreamr in numbers
AMR Impact
Life-sciences at the forefront of the battle against AMR
Development of National Action Plans
R&D
Biotechs
Diagnostics
from the blog
Drugs companies are rising to the challenges of research into superbugs
This letter was first published on the Financial Times on 4th July 2018, in response to the article titled "Pharma sector failing to tackle superbugs, says O’Neill" (26th June 2018) I respectfully disagree with Jim O’Neill’s comments on pharmaceutical companies’ inaction on combating ant...
Read more view all
